Open Access Lmumetadata only
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
klinik und poliklinik für frauenheilkunde und geburtshilfe, ddc:610
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 412759
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.